Pruritus clinical trials at University of California Health
3 in progress, 2 open to eligible people
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
“Volunteering for the GLISTEN trial could bring much-needed medical progress in PBC itch!”
open to eligible people ages 18-80
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
at UCSF
Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 12 years and up
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
at UC Davis
Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
Sorry, not accepting new patients
An open-label, single-arm, multi-centre program providing treatment access to ALGS patients with cholestatic pruritus in the US. Access can be requested through Clinigen Healthcare Ltd via email MirumALGS@clinigengroup.com or telephone +1-877-768-4303.
at UCLA UCSF
Our lead scientists for Pruritus research studies include Christopher Bowlus, MD Monika Sarkar.
Last updated: